# TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine

> **NCT01839149** · PHASE2 · COMPLETED · sponsor: **Trigemina, Inc** · enrollment: 240 (actual)

## Conditions studied

- High Frequency Episodic Migraine and Chronic Migraine

## Interventions

- **DRUG:** TI-001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01839149
- **Lead sponsor:** Trigemina, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2015-10
- **Final completion:** 2016-01
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2016-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01839149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01839149, "TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01839149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*